NCT01905813 2025-12-19Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesIncyte CorporationPhase 1 Active not recruiting121 enrolled
NCT04170283 2025-10-21Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell MalignanciesBeOne MedicinesPhase 3 Active not recruiting955 enrolled
NCT02457598 2025-06-17Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesGilead SciencesPhase 1 Terminated203 enrolled 43 charts
NCT04551963 2024-10-26Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell MalignanciesBeiGenePhase 1 Completed26 enrolled 20 charts
NCT02343120 2022-04-28Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid MalignanciesBeiGenePhase 1/2 Completed385 enrolled 29 charts 2 FDA
NCT03701438 2020-02-20Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With IdelalisibGilead SciencesTerminated2 enrolled